Revance Debuts DAXXIFY® Streaming TV Spot, “Relatable Moments,” Bringing Honest Aesthetics Conversations to a Wider Audience

Revance Debuts DAXXIFY® Streaming TV Spot, “Relatable Moments,” Bringing Honest Aesthetics Conversations to a Wider Audience

PR Newswire

The campaign celebrates the candid, “girl’s girl” moments that happen between women, even ones who just met.

NASHVILLE, Tenn., Nov. 16, 2026 /PRNewswire/ — Revance, a global aesthetics, regenerative and consumer skincare company, today announced the launch of its streaming TV spot for DAXXIFY® (daxibotulinumtoxinA-lanm for injection), the first and only frown line treatment with a peptide formulation.1-6 The streaming TV spot serves as part of the brand’s new campaign, “Relatable Moments,” which speaks to the word-of-mouth conversations that have helped DAXXIFY become the fastest-growing neurotoxin in the U.S.7 

DAXXIFY® Streaming TV Spot, “Relatable Moments”

“Today’s patients are not gatekeeping the aesthetic treatments they love, and ‘Relatable Moments’ was created to celebrate exactly that,” said Adelle Walker, Chief Marketing Officer, Aesthetics at Revance. “DAXXIFY is primed to amplify its message and reach new audiences nationwide through this milestone campaign.”

“Relatable Moments” features four women – starring Maya, an actual DAXXIFY patient sharing her authentic results – and captures the moments between them in the ladies’ room, swapping compliments, tips and recommendations without hesitation. True to the spirit of the campaign, Maya encourages her new friends to ask their providers about DAXXIFY. It is a reflection of the candid exchanges that have always defined how women show up for, and learn from, each other.

The “Relatable Moments” campaign will run on Netflix, Prime Video, Hulu, Disney+, HBO Max, YouTube, Meta and TikTok beginning today, November 16, 2026.

Visit DAXXIFY.com/look to learn more, see Maya’s before and after images and find a provider near you.

IMPORTANT SAFETY INFORMATION for DAXXIFY® (daxibotulinumtoxinA-Ianm) injection

DAXXIFY® may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of DAXXIFY®:

  • Problems swallowing, speaking, or breathing due to weakening of associated muscles can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months.
  • Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms that include loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing.

Do not receive DAXXIFY® if you are allergic to any of the ingredients in DAXXIFY® (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as rimabotulinumtoxinB (MYOBLOC®), onabotulinumtoxinA (BOTOX®/BOTOX® Cosmetic), abobotulinumtoxinA (DYSPORT®), incobotulinumtoxinA (XEOMIN®) or prabotulinumtoxinA-xvfs (JEUVEAU®), or have a skin infection at the planned injection site.

DAXXIFY® dosing units are not the same as, or comparable to, any other botulinum toxin product.

Tell your healthcare provider about all your medical conditions, including any side effects from botulinum toxin products, including dry eye; breathing, swallowing, bleeding, or heart problems; plans to have surgery; weakness of forehead muscles; drooping eyelids; have had surgery on your face; are pregnant or breastfeeding or plan to become pregnant or breastfeed.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using DAXXIFY® with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your healthcare provider that you have received DAXXIFY® in the past.

Especially tell your healthcare provider if you have received any other botulinum toxin product in the last 4 months or any in the past, and exactly which product you received (such as BOTOX®, BOTOX® Cosmetic, MYOBLOC®, DYSPORT®, XEOMIN®, or JEUVEAU®). 

DAXXIFY® may cause serious side effects, including allergic reactions (such as itching, rash, redness, swelling, wheezing, trouble breathing, or dizziness or feeling faint), heart problems (such as irregular heartbeat and heart attack), and eye problems (including dry eye, reduced blinking, and corneal problems). Tell your healthcare provider or get medical help right away if you experience a serious side effect. No serious adverse events of distant spread of toxin effect associated with dermatologic use of DAXXIFY® have been reported in clinical studies at the dose of 40 Units for glabellar lines. The most common side effects of DAXXIFY® include headache, eyelid drooping, and loss of ability to move the muscles in your face.

These are not all the possible side effects of DAXXIFY®. For more information, see the full Prescribing Information including Boxed Warning, and refer to the Medication Guide or talk with your doctor. To report side effects associated with DAXXIFY®, please call 1-877-373-8669. You may also report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.

APPROVED USE
DAXXIFY® is a prescription medicine that is injected into muscles and used in adults to temporarily improve the look of moderate to severe frown lines between the eyebrows.

About Revance
Revance is a fast-growing global aesthetics and skincare company focused on providing innovative aesthetics and market-leading skincare offerings throughout every stage of life. With a differentiated portfolio of products spanning 60 countries, Revance meets the evolving needs of patients and consumers worldwide through continued innovation and commercialization of new products and treatments.

Focused on skin science for life, Revance’s extensive portfolio includes leading brands within the aesthetics, consumer skincare, regenerative, and therapeutics segments.

Aesthetics offerings include: DAXXIFY® (daxibotulinumtoxinA-lanm) for injection; the RHA® Collection of dermal fillers by Teoxane SA; SkinPen®, an industry-leading microneedling device; MicroPen EVO®, an FDA-cleared microneedling device; ProGen PRP®, a gold standard in Platelet-Rich Plasma; and Biojuve®, a clinically proven living microbe technology, among others. Revance’s strong consumer skincare portfolio includes brands such as PanOxyl®, Blue Lizard®, StriVectin®, Sarna®, Zeasorb®, Desenex®, and Keri®.

Learn more at Revance.com.

Media Contact
EvolveMKD
Revance@EvolveMKD.com 

DAXXIFY® is a registered trademark of Revance Therapeutics, Inc. All other trademarks are the property of their respective owners.

References

  1. DAXXIFY®. Prescribing Information. Revance Therapeutics, Inc; 2023.
  2. BOTOX® Cosmetic. Prescribing Information. Allergan Inc; 2023.
  3. XEOMIN®. Prescribing Information. Merz Pharmaceuticals GmbH; 2024.
  4. DYSPORT®. Prescribing Information. Ipsen Biopharmaceuticals, Ltd; 2023.
  5. JEUVEAU®. Prescribing Information. Evolus, Inc; 2020.
  6. LETYBO®. Prescribing Information. Hugel, Inc; 2024.
  7. Data on file. US Facial Injectables Market Tracker 2025, p10A.

DAXI-02050

Revance Logo

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/revance-debuts-daxxify-streaming-tv-spot-relatable-moments-bringing-honest-aesthetics-conversations-to-a-wider-audience-302939452.html

SOURCE Revance